ABD, EVP, Clinical Research
IMA Clinical Research
Michael Minor is a senior business executive with strategic vision and entrepreneurial spirit. His career encompasses over 40 years of clinical research experience at pharmaceutical companies, service providers and research sites. His global leadership experience spans multiple business segments which provides him with a balanced industry perspective of Sponsor and Provider roles and goals. He has broad therapeutic experience and directed or participated in over 200 clinical trials spanning Phase I through IV resulting in approvals of more than 30 new products. Operational delivery command includes interventional, pragmatic and observational research models. Mr. Minor uses this subject matter expertise, commercial sensibility, and balanced insight to drive synthesis of new business delivery strategies, leading to organizational growth and expanded profitability. Mr. Minor built a CRO (ACER/Excel) from the ground up and successfully orchestrated sale of the business at an industry-leading multiple. Mr. Minor has the demonstrated ability to build, integrate and expand commercial and clinical operations as proven in multiple CROs.
Mr. Minor’s career has been built on roles with increasing responsibility and geographical reach. On the Pharma side, he has held the roles of Clinical Scientist, Project Director and Sr. Director Outsourcing Operations. On the service provider side, he has held the titles of President, VP Strategic Accounts, VP Regional Operations, VP Late Phase Research, Sr. VP. Proposals and Business Information, Sr. VP Strategic Planning & Proposals, Sr. VP. Global Head, Peri-Approval & Observational Research, and VP Strategic Proposals & Business Information. Mr. Minor is currently building a new site network that supports decentralized/hybrid trials and brings advanced treatments to diverse patient populations.
Mr. Minor earned a Bachelor of Science from Syracuse University and is all but dissertation for his PhD in Microbiology from Rutgers University.